LIFE aTyr Pharma

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial results and provide a corporate update after the market close on Thursday, August 13, 2020.

Conference Call and Webcast Details:

Thursday, August 13th @ 5:00 p.m. EDT / 2:00 p.m. PDT

Domestic:  844-358-9116

International:  209-905-5951

Conference ID:  5176802

Webcast:

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit . 

Contact:
Ashlee Dunston
Investor Relations, aTyr Pharma

EN
06/08/2020

Underlying

LIFEaTyr Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on aTyr Pharma

 PRESS RELEASE
Free
LIFE ATYR PHARMA

 aTyr Pharma to Present at Upcoming Investor Conferences

 aTyr Pharma to Present at Upcoming Investor Conferences SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at several upcoming investor conferences scheduled to take place in May and June 2025. Details of the conferences appear below: Conference: RBC Capital Markets Global Healthcare ConferenceDate: Wednes...

May 20, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thor...

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity. Treatment practices in the U.S. show approximately 75% of diagnosed pulmonary sarcoidosis patients require treatment with steroi...

May 19, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635...

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 36,200 shares of aTyr’s common stock, each with an exercise price of $3.00 per share, which is equal ...

May 16, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fib...

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has advan...

May 14, 2025 1 EN
 PRESS RELEASE
Free
LIFE ATYR PHARMA

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporat...

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch